In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 51 to 100 of 342

Sort by

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over ID6448	Technology appraisal guidance	22 July 2026
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]	Technology appraisal guidance	TBC
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]	Technology appraisal guidance	TBC
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]	Technology appraisal guidance	24 May 2019
Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]	Technology appraisal guidance	TBC
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]	Technology appraisal guidance	TBC
Camizestrant as an add-on to palbociclib and abemaciclib for untreated hormone receptor-positive HER2-negative metastatic breast cancer with an ESR1 mutation [ID6535]	Technology appraisal guidance	TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]	Technology appraisal guidance	TBC
Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency [ID6466]	Technology appraisal guidance	TBC
Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]	Technology appraisal guidance	30 September 2026
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]	Technology appraisal guidance	TBC
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]	Technology appraisal guidance	TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]	Technology appraisal guidance	TBC
Colon cancer (adjuvant) - irinotecan [ID379]	Technology appraisal guidance	TBC
Concizumab for treating haemophilia A or B in people 12 years and over with inhibitors [ID6665]	Technology appraisal guidance	TBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]	Technology appraisal guidance	TBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]	Technology appraisal guidance	TBC
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]	Technology appraisal guidance	25 February 2026
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]	Technology appraisal guidance	4 March 2026
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297	Technology appraisal guidance	TBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297	Technology appraisal guidance	28 July 2021
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]	Technology appraisal guidance	TBC
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]	Technology appraisal guidance	TBC
Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]	Technology appraisal guidance	TBC
DCVax-L for treating glioblastoma [ID836]	Technology appraisal guidance	TBC
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]	Technology appraisal guidance	TBC
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897	Technology appraisal guidance	TBC
Depemokimab for treating chronic rhinosinusitis with nasal polyps [ID6449]	Technology appraisal guidance	TBC
Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447]	Technology appraisal guidance	25 March 2026
Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over [ID6160]	Technology appraisal guidance	TBC
Deuruxolitinib for treating severe alopecia areata ID6597	Technology appraisal guidance	TBC
Deutetrabenazine for treating tardive dyskinesia ID6550	Technology appraisal guidance	TBC
Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TS ID 10725]	Technology appraisal guidance	TBC
Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726	Technology appraisal guidance	TBC
Diabetic retinopathy - ruboxistaurin [ID382]	Technology appraisal guidance	TBC
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]	Technology appraisal guidance	TBC
Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]	Technology appraisal guidance	18 June 2026
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]	Technology appraisal guidance	TBC
Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency [ID6415]	Technology appraisal guidance	12 January 2026
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]	Technology appraisal guidance	TBC
Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID6235	Technology appraisal guidance	11 February 2026
Dupilumab for treating bullous pemphigoid [ID6479]	Technology appraisal guidance	TBC
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]	Technology appraisal guidance	TBC
Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648) [ID6480]	Technology appraisal guidance	TBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]	Technology appraisal guidance	TBC
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]	Technology appraisal guidance	TBC
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]	Technology appraisal guidance	TBC
Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168]	Technology appraisal guidance	17 December 2025
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317	Technology appraisal guidance	TBC
Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]	Technology appraisal guidance	14 April 2027

Results per page

10
25
50
All